For research use only
| Cat No. | ABC-X0295C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human BRAF (G464V) BAF3 Cell Line enables detailed research on BRAF mutations involved in MAPK pathway dysregulation and therapy resistance.
Human BRAF (G464V) BAF3 Cell Line is derived from Ba/F3 cells through stable lentiviral integration of human BRAF carrying the G464V mutation. Expanded below passage 20, gene overexpression is confirmed by qRT-PCR.
Target
The G464V mutation enhances BRAF kinase activity and occurs in a subset of solid tumors, such as colorectal and thyroid cancer. It is associated with RAF dimerization and MEK-ERK hyperactivation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0295C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model enables drug screening against non-V600 BRAF mutants and supports mechanistic studies of RAF dimer-targeted strategies.